CTL019

January 18, 2018January 18, 2018

FDA Promises Rapid Review of Kymriah for Diffuse Large B-cell Lymphoma

News

The U.S. Food and Drug Administration (FDA) will prioritize the regulatory review of Novartis’ application to use Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large ... Read more

November 8, 2017

Novartis Files for Approval of Kymriah for Two Blood Cancers in the EU

News

Novartis continues the process of making Kymriah (tisagenlecleucel) commercially available outside the U.S., now by applying with the European Medicines Agency (EMA) to approve the treatment for two types of ... Read more

June 15, 2017

37% of Those Who Received CTL019 in Phase 2 Clinical Trial Had Their Lymphoma Disappear

News

Thirty-seven percent of patients with a difficult-to-treat lymphoma had their cancer disappear after receiving Novartis’ CTL019 (tisagenlecleucel), according to an interim analysis of Phase 2 clinical trial results. Other patients achieved ... Read more

April 20, 2017

Novartis’ CTL019 Receives Breakthrough Therapy Designation for the Treatment of Certain DLBCL Patients

News

Novartis‘ CAR T-cell therapy CTL019 has received breakthrough therapy status by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed and refractory diffuse large B-cell ... Read more

November 21, 2016

Novartis to Present New Data on Potential Lymphoma Treatments

News

Novartis will present the most recent clinical data from its cancer research program at the upcoming 58th American Society of Hematology (ASH) Annual Meeting & Exposition Dec. 3-6 in San Diego and ... Read more

December 9, 2015May 13, 2016

Non-Hodgkin Lymphoma Study of Novartis’ T-cell Therapy Shows Early Efficacy

News

Novartis has released findings from a Phase 2a study evaluating the safety and efficacy of its novel chimeric antigen receptor T-cell (CART) immunotherapy CTL019 in two types of relapsed or refractory non-Hodgkin Lymphoma. The data was presented ... Read more